The Denial Rate Nobody Puts on the Board Deck
The molecular diagnostics denial rate sits at roughly 35.3 percent (XiFin) of billed CPT codes, and prior authorization is the single most frequent reason. That number rarely makes it into a board deck, because by the time anyone’s building the deck, it’s already been absorbed into write-offs, rework, and an appeals team’s monthly numbers. This piece is about what that number actually costs, and why the fix belongs at order intake, not in the appeals queue.
Why This Is an Upstream Problem, Not a Billing Problem
Prior authorization denials in molecular and genetic testing rose 24 percent (XiFin) in a single measured period (2023), the fastest-growing denial category in the segment. The pattern behind most of them is the same, missing or incomplete documentation at the point the test was ordered, not a coding mistake caught later. Your billing team didn’t create this problem. They inherited it.
Your billing team didn’t create this problem. They inherited it.
What a 12 to 24 Month ROI Bar Actually Requires
New technology spend doesn’t get approved on a good story, it gets approved on a number that survives a finance team’s scrutiny. At scale, a few points of preventable denial rate translate directly into write-offs and rework hours, both of which show up on a P&L in ways a board will ask about. The case for fixing this upstream isn’t a documentation-quality argument. It’s a payback-period argument, and it needs to be built the same way any other capital request is built.
The Cost of Manual Chasing at Scale
When a molecular test order comes in missing a piece, someone has to go get it, a call, a fax, a message to the ordering provider. That works fine at low volume. It doesn’t scale, because the chasing grows with patient volume and your team doesn’t. Every hour spent chasing a missing detail is an hour not spent on the claims that are already clean, and the cost of that tradeoff rarely gets its own line item, which is exactly why it’s easy to underestimate.
Every hour spent chasing a missing detail is an hour not spent on the claims that are already clean.
Closing the Gap at Test-Order
xCures® is the Clinical Clarity Engine for healthcare, assembling and structuring patient medical records into decision-ready data. xCures’ Decision-Ready Checklists match a payer’s own coverage criteria against what the patient’s record already contains at the point of test order rather than after a denial. Automated Patient History assembles the longitudinal record automatically, and Evidence Grade Data gives that record traceability back to its source. This doesn’t replace your RCM or billing system. It removes the upstream documentation gap before that system ever has to process a claim built on incomplete information.
Closing the gap at order intake is what actually brings the molecular diagnostics denial rate down from that 35.3 percent, not appealing more claims after the fact.
What the Numbers Show
NeoGenomics closed a roughly $1 million reimbursement gap and cut bad debt faster than any prior approach they’d tried.* xCures processes more than 1.5 million documents per day, across more than 550,000 care locations.* Extractors are validated against clinical review, not the output itself, giving 99.7 percent combined accuracy across 200-plus comorbidity assessments.* None of this replaces your finance team’s model. It gives that model a stronger number to build from.
*Results based on a retrospective analysis of a defined historical dataset and do not guarantee future performance.
Where This Falls Short
Fixing documentation at intake reduces the denials that trace back to missing or incomplete records. It doesn’t eliminate payer policy volatility, coverage disputes over experimental status, or every edge case a molecular test can run into. Some of that 35.3 percent will always need a human reviewer and a real appeal. This closes the largest and most preventable share of it, not all of it.
See what xCures would have caught before your last denial.
30-min demo, no prep required.
Frequently asked.
What is the molecular diagnostics denial rate, and why is it so high?
It’s the share of molecular and genetic test claims that get denied by payers, currently around 35.3 percent of billed CPT codes in this segment. It runs high because these tests carry heavier documentation requirements, and prior authorization is the fastest-growing denial category in the segment, most denials trace back to missing or incomplete information captured at the point the test was ordered.
What kind of payback period should we expect?
That depends on test mix and current denial rate, so we won’t put a single number here. What we can show in a demo is exactly what a Decision-Ready Checklist would have flagged against a real order, so your team can build its own model from there.
Why does chasing missing documentation stop scaling as volume grows?
Chasing a missing detail by phone or fax takes a fixed amount of time no matter how big your lab gets. Patient volume grows, but your team doesn’t grow at the same rate, so the backlog compounds.
How is this different from working with an RCM or billing partner like XiFin?
RCM platforms manage the claim once it’s built, submission, appeals, payment posting. xCures works upstream of that, structuring the patient record and flagging documentation gaps before the claim is ever built, so fewer claims arrive at your RCM system already incomplete.
What proof does xCures have that this approach works?
xCures processes more than 1.5 million documents per day, with extractors validated against clinical review, giving 99.7 percent combined accuracy across 200-plus comorbidity assessments.* Results based on a retrospective analysis of a defined historical dataset and do not guarantee future performance.
Does this replace our appeals process?
No. It reduces how often you need one. Some denials, especially coverage disputes and experimental-status determinations, will still need a human reviewer and a real appeal.